By PR Newswire
September 11, 2026 | 14:54
Kazia Therapeutics initiated dosing in its PNOC035 clinical study evaluating drug candidate paxalisib alongside gemcitabine for children and young adults with recurrent AT/RT brain cancer.
By PR Newswire
September 11, 2026 | 14:50
Transcenta Therapeutics partnered with WuXi Biologics under a strategic agreement to accelerate the commercialisation and deployment of its proprietary HiCB continuous bioprocessing manufacturing technologies.
By PR Newswire
September 10, 2026 | 15:26
Human resources provider HR Path acquired tts digital HR experts GmbH to expand its consulting capabilities, technical implementation, and application management services for SAP SuccessFactors software.
By PR Newswire
September 10, 2026 | 15:11
Sceye completed a 30-day, 30,000-kilometre stratospheric flight between the United States and Japan, successfully verifying direct-to-device mobile connectivity alongside SoftBank Corporation.
By PR Newswire
September 10, 2026 | 14:59
LattePanda launched its Mu Ultra compute module featuring Intel Core Ultra processors, delivering up to 115 TOPS of artificial intelligence processing performance in a compact form factor.
By PR Newswire
September 10, 2026 | 14:46
Harbour BioMed partner Solstice Oncology secured $225 million in Series A financing to advance porustobart, a novel neoadjuvant immuno-oncology therapy targeting diverse cancer treatments.
By PR Newswire
September 10, 2026 | 11:20
Triple Whale unveiled a rebranded identity marking its operational transition from an e-commerce analytics platform into an integrated AI operating system for modern commercial enterprises.
By PR Newswire
September 10, 2026 | 11:17
SAP Gold Partner Accely appointed Michael Lim as Director of Strategy and Growth for Singapore and Southeast Asia to manage regional commercial strategy and corporate expansion.
By PR Newswire
September 10, 2026 | 11:08
Pexar introduced the PexarBolt Ultra TBT5 Dock equipped with a 5-inch visual dashboard, 10GbE network port, CFexpress Type B slot, and dedicated solid-state drive bay.
By PR Newswire
September 10, 2026 | 11:01
Alebund Pharmaceuticals received U.S. Food and Drug Administration investigational new drug clearance to commence clinical trials for AP308, targeting treatment of IgA nephropathy kidney disease.